Briacell Therapeutics Corp (BCTX) Stock Price, Quote & News

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 921 1810

Fax: 604 921 1898

Website: briacell.com

Address:

Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

TWBXX Apr. 28 at 12:08 AM

$BCTX Yes — if BriaCell updates the Phase 2 dataset at ASCO, the OS can absolutely go up because the surviving patients in that cohort have continued to live months (or even years) longer since the last published cutoff. And the ASCO press release you’re viewing confirms they are presenting updated survival data: “Final randomized Phase 2 Bria‑IMT survival and quality of life data to be presented.” That means the OS curve is not frozen. It continues to mature.

1 · Reply

TWBXX Apr. 27 at 9:01 PM

$BCTX Per Co-Pilot: If BriaCell’s Phase 3 in late‑line, heavily pretreated metastatic breast cancer shows OS equal to or better than their Phase 2 signal, they could plausibly have best‑in‑class OS in that specific refractory setting versus historical expectations and many current options in that line of therapy. That’s the core of the bull thesis.

0 · Reply

SuperGreenToday Apr. 27 at 8:33 PM

$BCTX

0 · Reply

TWBXX Apr. 27 at 8:21 PM

$BCTX Nice close!

0 · Reply

jfun1 Apr. 27 at 7:39 PM

$BCTX 30 million mkt cap. Crazy if their drug works. Worth a swing imo

0 · Reply

SmallCapGrowth Apr. 27 at 5:10 PM

BB's Stock Haven : NASDAQ News Alert: $BCTX to showcase six... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177543542 via @Investors_Hub

0 · Reply

laaarsas Apr. 27 at 5:00 PM

$BCTX What is this donkey case?

0 · Reply

laaarsas Apr. 27 at 4:54 PM

$BCTX Wassup donkeys?

0 · Reply

SmallCapGrowth Apr. 27 at 4:34 PM

NASDAQ News Alert: $BCTX to showcase six clinical data presentations at ASCO 2026 - survival and quality of life data plus biomarker analyses from its ongoing Phase 3 study. A major catalyst to watch as the company advances. NEWS: https://globenewswire.com/news-release/2026/04/27/3281510/0/en/briacell-announces-six-clinical-data-presentations-at-asco-2026.html

0 · Reply

SmallCapGrowth Apr. 27 at 4:32 PM

0 · Reply

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

2026-04-21T13:28:43.000Z - 6 days ago

BriaCell (BCTX) Showcases Promising Data at AACR Annual Meeting

Tue, 21 Apr 2026 07:30:00 -0400 - 6 days ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

2026-04-20T13:32:04.000Z - 7 days ago

BriaCell (BCTX) Showcases Positive Clinical Data at AACR Annual Meeting

Mon, 20 Apr 2026 07:30:00 -0400 - 7 days ago

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

Tue, 31 Mar 2026 16:05:00 -0400 - 27 days ago

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

2026-03-18T13:30:56.000Z - 5 weeks ago

BriaCell (BCTX) to Reveal Key Findings at 2026 AACR Annual Meeting

Wed, 18 Mar 2026 07:30:00 -0400 - 5 weeks ago

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

Tue, 10 Mar 2026 07:30:00 -0400 - 6 weeks ago

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

Thu, 05 Mar 2026 16:04:00 -0500 - 7 weeks ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

2026-02-18T22:51:30.000Z - 2 months ago

BriaCell (BCTX) Expands Biologic Cancer Treatments Through New Agreement

Wed, 18 Feb 2026 17:30:00 -0500 - 2 months ago

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

Tue, 17 Feb 2026 07:30:00 -0500 - 2 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

2026-01-28T13:30:56.000Z - 3 months ago

BriaCell Therapeutics (BCTX) Shows Promising Results in Metastatic Breast Cancer Treatment

Wed, 28 Jan 2026 07:30:00 -0500 - 3 months ago

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

2026-01-27T13:32:37.000Z - 3 months ago

BriaCell (BCTX) Reports Promising Phase 2 Survival Data

Tue, 27 Jan 2026 07:30:00 -0500 - 3 months ago

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

2026-01-19T16:00:45.000Z - 3 months ago

Is the Market Bullish or Bearish on BriaCell Therapeutics Corp?

2026-01-16T13:58:57.000Z - 3 months ago

Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch

Thu, 15 Jan 2026 16:05:00 -0500 - 3 months ago

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

2026-01-14T11:36:30.000Z - 3 months ago

What's Going On With BriaCell Therapeutics Stock Wednesday?

2026-01-14T11:19:44.000Z - 3 months ago

BriaCell Plunges On Pricing Announcement Of $30Mln Public Offering

2026-01-14T10:55:53.000Z - 3 months ago

BriaCell (BCTX) Unveils $30M Public Offering, Stock Dips 9.7%

2026-01-14T06:56:44.000Z - 3 months ago

BriaCell Therapeutics (BCTX) Launches $30M Public Offering

Tue, 13 Jan 2026 21:00:00 -0500 - 3 months ago

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

2026-01-13T20:32:32.000Z - 3 months ago

BCTX Surges On Positive Clinical Response In Metastatic Cancer Immunotherapy Study

2026-01-13T14:08:02.000Z - 3 months ago

BriaCell Surge Above 50%; What's The Buzz?

2026-01-13T12:53:09.000Z - 3 months ago

BriaCell (BCTX) Reports Impressive Lung Metastasis Resolution in Cancer Trial

Tue, 13 Jan 2026 07:30:00 -0500 - 3 months ago

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

Thu, 18 Dec 2025 07:30:00 -0500 - 4 months ago

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

2025-12-10T13:29:00.000Z - 4 months ago

BriaCell (BCTX) Highlights Promising Data at 2025 SABCS Symposium

Wed, 10 Dec 2025 07:30:00 -0500 - 4 months ago

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

2025-12-09T13:34:16.000Z - 4 months ago

BriaCell (BCTX) Progresses with Phase 3 Study in Metastatic Breast Cancer

Tue, 09 Dec 2025 07:30:00 -0500 - 4 months ago

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

2025-12-02T12:50:27.000Z - 5 months ago

BriaCell (BCTX) Shares Positive Clinical Results Ahead of 2025 Symposium

Tue, 02 Dec 2025 07:30:00 -0500 - 5 months ago

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

2025-12-01T12:53:14.000Z - 5 months ago

Bicara Therapeutics (BCTX) Releases Promising Early Data from Cancer Drug Trial

Tue, 25 Nov 2025 07:30:00 -0500 - 5 months ago

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

2025-11-20T13:28:07.000Z - 5 months ago

BriaCell (BCTX) Partners with Receptor.AI for Innovative Cancer Drug Development

Thu, 20 Nov 2025 07:30:00 -0500 - 5 months ago

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Tue, 18 Nov 2025 07:30:00 -0500 - 5 months ago

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Fri, 07 Nov 2025 07:30:00 -0500 - 6 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Tue, 04 Nov 2025 07:30:00 -0500 - 6 months ago

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

2025-10-28T08:01:00.000Z - 6 months ago

Zacks.com featured highlights include Groupon, BriaCell Therapeutics and InnovAge Holding

2025-10-27T19:05:00.000Z - 6 months ago

Top 3 Earnings Acceleration Buys for November

2025-10-22T12:51:17.000Z - 6 months ago

BriaCell (BCTX) Receives Positive Safety Endorsement for Phase 3 Cancer Study

Wed, 22 Oct 2025 07:30:00 -0400 - 6 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

2025-10-21T20:52:14.000Z - 6 months ago

BriaCell Rises On Phase 3 Expansion And MSK Collaboration

2025-10-21T13:25:38.000Z - 6 months ago

BriaCell (BCTX) Expands Phase 3 Cancer Study with New Major Centers

2025-10-21T12:50:54.000Z - 6 months ago

BriaCell (BCTX) Partners with MSK for Cancer Immunotherapy Development

Oct 21, 2025, 7:50 AM EDT - 6 months ago

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

Oct 21, 2025, 7:30 AM EDT - 6 months ago

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Oct 20, 2025, 7:30 AM EDT - 6 months ago

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Oct 13, 2025, 7:30 AM EDT - 7 months ago

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Oct 3, 2025, 7:30 AM EDT - 7 months ago

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

Aug 26, 2025, 7:30 AM EDT - 8 months ago

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Aug 25, 2025, 7:30 AM EDT - 8 months ago

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

Aug 21, 2025, 12:00 PM EDT - 8 months ago

BriaCell Announces Proposed Effective Date of Share Consolidation

Aug 13, 2025, 7:30 AM EDT - 9 months ago

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

Jul 31, 2025, 7:30 AM EDT - 9 months ago

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

Jul 30, 2025, 7:30 AM EDT - 9 months ago

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

Jul 29, 2025, 7:30 AM EDT - 9 months ago

BriaCell's Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

Jul 25, 2025, 7:30 AM EDT - 9 months ago

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

Jul 16, 2025, 4:05 PM EDT - 10 months ago

BriaCell Therapeutics Announces Closing of $15 million Public Offering

Jul 15, 2025, 3:05 PM EDT - 10 months ago

BriaCell Therapeutics Announces Pricing of $15 million Public Offering

Jul 15, 2025, 7:30 AM EDT - 10 months ago

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

Jul 11, 2025, 7:30 AM EDT - 10 months ago

BriaCell's Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

Jul 10, 2025, 7:30 AM EDT - 10 months ago

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient

Jul 9, 2025, 7:30 AM EDT - 10 months ago

BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study

Jul 8, 2025, 7:30 AM EDT - 10 months ago

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

Jul 2, 2025, 7:30 AM EDT - 10 months ago

BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven

Jun 24, 2025, 7:30 AM EDT - 10 months ago

BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

Jun 4, 2025, 7:30 AM EDT - 11 months ago

BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26

Jun 2, 2025, 7:30 AM EDT - 11 months ago

BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025

May 27, 2025, 7:30 AM EDT - 11 months ago

BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor

May 23, 2025, 7:30 AM EDT - 1 year ago

BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025

May 20, 2025, 7:30 AM EDT - 1 year ago

BriaCell CEO Letter to Shareholders

TWBXX Apr. 28 at 12:08 AM

1 · Reply

TWBXX Apr. 27 at 9:01 PM

0 · Reply

SuperGreenToday Apr. 27 at 8:33 PM

$BCTX

0 · Reply

TWBXX Apr. 27 at 8:21 PM

$BCTX Nice close!

0 · Reply

jfun1 Apr. 27 at 7:39 PM

$BCTX 30 million mkt cap. Crazy if their drug works. Worth a swing imo

0 · Reply

SmallCapGrowth Apr. 27 at 5:10 PM

BB's Stock Haven : NASDAQ News Alert: $BCTX to showcase six... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177543542 via @Investors_Hub

0 · Reply

laaarsas Apr. 27 at 5:00 PM

$BCTX What is this donkey case?

0 · Reply

laaarsas Apr. 27 at 4:54 PM

$BCTX Wassup donkeys?

0 · Reply

SmallCapGrowth Apr. 27 at 4:34 PM

0 · Reply

SmallCapGrowth Apr. 27 at 4:32 PM

0 · Reply

SmallCapGrowth Apr. 27 at 3:21 PM

0 · Reply

ZacksResearch Apr. 27 at 2:49 PM

$BCTX gearing up for a major ASCO spotlight — is this the next biotech catalyst? 👀 BriaCell just announced 3 clinical poster presentations + 3 publication-only abstracts at the 2026 ASCO Annual Meeting, highlighting Bria-IMT + CPI data, survival outcomes, and ongoing Phase 3 biomarker analysis in metastatic breast cancer — with full details dropping May 21. Big-stage exposure + upcoming data visibility could put this name on traders’ radar fast. See what Wall Street expects next 👉 https://www.zacks.com/stock/research/BCTX/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-teaser-37913&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_TEASER_37913

0 · Reply

SmallCapGrowth Apr. 27 at 1:54 PM

BriaCell Therapeutics Corp ( $BCTX ): $BCTX to showcase six clinical data pres... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177542406 via @Investors_Hub

0 · Reply

JediGreen Apr. 27 at 1:52 PM

$BCTX The way it’s worded at the end of this PR . Abstract Title: Monitoring blood-based biomarkers as early predictors of progression-free survival in a randomized Bria-ABC phase 3 trial for advanced metastatic breast cancer: An ongoing analysis. Session Type/Title: Poster Session - Developmental Therapeutics—Immunotherapy Poster Board: 442 Date and Time: May 30, 2026, 1:30 PM-4:30 PM CDT

2 · Reply

SmallCapGrowth Apr. 27 at 1:46 PM

$BCTX to showcase six clinical data presentations at ASCO 2026, including final randomized Phase 2 Bria-IMT survival and quality of life data plus biomarker analyses from its ongoing Phase 3 study. A major catalyst to watch as the company advances. https://globenewswire.com/news-release/2026/04/27/3281510/0/en/briacell-announces-six-clinical-data-presentations-at-asco-2026.html #Stocks #stockstobuy #stockstowatch #investors #BCTX @smallcapvoice

0 · Reply

MoeMaze Apr. 27 at 12:37 PM

$BCTX BCTX has officially invented a new market strategy: Good news = stock goes down. More good news = stock goes down faster. At this rate, please stop the updates before it reaches the Dead Sea scrolls. Amazing science, confusing chart.

1 · Reply

SmallCapVoice Apr. 27 at 11:34 AM

$BCTX is set to showcase six clinical data presentations at ASCO 2026, including final randomized Phase 2 Bria-IMT survival and quality of life data plus biomarker analyses from its ongoing Phase 3 study. A major catalyst to watch as the company advances. https://www.globenewswire.com/news-release/2026/04/27/3281510/0/en/briacell-announces-six-clinical-data-presentations-at-asco-2026.html

0 · Reply

JJBurch Apr. 27 at 8:31 AM

$OSRH 🚨 🚨 🚨 critical week where it breaks out. As of late March/April 2026, analysts have set a 12-month price target for OSR Holdings (OSRH) at $10.00, representing a potential massive upside from current levels near $0.60–$0.70. This bullish target is driven by potential milestone payments of up to $815 million from a licensing term sheet for VXM01 and global interest in their Woori IO non-invasive glucose monitor. Yahoo Finance Yahoo Finance +4 Average Target: $10.00 to $10.20 per share. $BCTX $IXHL $MITQ $PLTR

0 · Reply

JJBurch Apr. 27 at 8:24 AM

$OSRH $10+ price target for 2026 You do the math Congrats on finding this one Is a life changing opportunity $IXHL $MITQ $BCTX $PLTR

0 · Reply

JediGreen Apr. 27 at 12:46 AM

$BCTX

0 · Reply

JediGreen Apr. 27 at 12:46 AM

$BCTX Renmark Virtual Non-Deal Roadshow: TSX - BCT | NASDAQ - BCTX (ID 2854) https://renmark-drupal.s3.amazonaws.com/vndr/briacell-therapeutics-corp/2026-02-12-11-00-00/index.html

0 · Reply

Rohtan Apr. 26 at 3:39 AM

$BCTX

0 · Reply

Market Cap	28.13M
Revenue (ttm)	0.00
Net Income (ttm)	-26.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	117,600
Avg Vol	201,758
Day's Range	N/A - N/A
Shares Out	7.25M
Stochastic %K	18%
Beta	1.30
Analysts	Strong Buy
Price Target	$40.00